subject: The new results become difficult to enter the market barriers to innovation and development of pharmaceutical companies - pharmaceutical companies, [print this page] The new results become difficult to enter the market barriers to innovation and development of pharmaceutical companies - pharmaceutical companies,
China is the world's largest producer of bulk drugs, more drugs consumer, the face of increasingly fierce international competition, China's pharmaceutical enterprises to strengthen self-developed medicines urgently.
Independent research and development in the pharmaceutical business innovation, domestic pharmaceutical companies and foreign companies have significant gaps, such as the proportion of investment in R & D expenditures in research and development costs of large foreign companies can usually 10% of sales? 15%, in Taiwan Pharmaceutical R & D investment and more cost no more than 3% of sales, general business only 0.5% of sales? 1.0%.
Recently, the State Council Development Research Center "Enhancing the ability of independent innovation system, mechanism and policy research" discussion group "published by innovation policy needs to encourage the market launch of innovative products," the report analyzes the early market innovative products in China is difficult to start, not technological innovation into economic benefits, the lack of continuous innovation and dynamic enterprises, innovation is difficult to enter the market situation is restricting innovation pharmaceutical companies take the initiative to the major factors. Experts pointed out that only the market mechanism to encourage innovation to achieve, can truly and fully mobilize the initiative of independent research and development enterprise.
Drugs in foreign markets, through innovative research and development of products in clinical trials and strict quality control standards, the market will soon open the market, there are a number of incentive policies to accelerate innovation and market drugs of good economic and corporate R & D between market formed a virtuous circle. Contrast, the domestic situation, some independent innovation products to export overseas is difficult in domestic sales, higher standards can be certified but not domestic, foreign certification.
Edge of Pharmaceutical Health Ministry of Science and bear a major key projects, carry out international research of Chinese medicine, its Guizhifuling FDA capsule has been officially approved by the U.S. to enter phase II clinical trials, the standard fingerprint Guizhifuling capsule was U.S. FDA approval, but to apply the standard found in the country still could not be approved. North China Pharmaceutical, Double-Crane Pharma and other drug companies to increase R & D also received some breakthrough drugs in the current bidding and pricing system, even if the price of foreign drug patent expired drugs is also made more than 10 times corporate profits Debu to protect. In this case, the domestic pharmaceutical companies marketing side is the high cost of patented innovation, the other side is the pricing system, and many other restrictions, which can easily lead to innovative enterprises do not see the earnings outlook, causing the results of research had to be up a temporary reserve situation.
The ultimate goal of independent innovation and create economic benefits through the market, if there is no market innovative products to fill technology gaps and break the monopoly on foreign technology will have no real meaning. The report recommends the Government should demand through innovative incentives for enterprises to create a market environment conducive to innovation, including elimination of market entry barriers, and expand the procurement of new products as soon as possible so that economies of scale of production, raise the mandatory standard to speed up eliminating backward products to release the right market space consumption.
